Illumina collaborates with MyOme with strategic investment for clinical trial, potentially saving US healthcare $200B/year.
Illumina, Inc. (NASDAQ: ILMN) and MyOme have collaborated in a partnership merging Illumina's top sequencing technology with advanced clinical genomics analyses and artificial intelligence. This alliance aims to propel precision medicine for early detection and prevention. The partnership was announced in San Diego and Menlo Park, California, on December 11, 2025.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments